Selective Estrogen Receptor Modulators.
10.4184/asj.2016.10.4.787
- Author:
Ki Chan AN
1
Author Information
1. Department of Orthopaedic Surgery, Busan Paik Hospital College of Medicine, Inje University, Busan, Korea. osahnkc@inje.ac.kr
- Publication Type:Review
- Keywords:
Osteoporosis;
Selective estrogen receptor modulators
- MeSH:
Breast Neoplasms;
Chemistry, Pharmaceutical;
Estrogens;
Female;
Fractures, Compression;
Humans;
Incidence;
Osteoporosis;
Osteoporosis, Postmenopausal;
Raloxifene Hydrochloride;
Selective Estrogen Receptor Modulators*;
Tamoxifen
- From:Asian Spine Journal
2016;10(4):787-791
- CountryRepublic of Korea
- Language:English
-
Abstract:
Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen agonist and an antagonist, depending on the target tissue. After tamoxifen, raloxifene, lasofoxifene and bazedoxifene SERMs have been developed and used for treatment. The clinically decisive difference among these drugs (i.e., the key difference) is their endometrial safety. Compared to bisphosphonate drug formulations for osteoporosis, SERMs are to be used primarily in postmenopausal women of younger age and are particularly recommended if there is a family history of invasive breast cancer, as their use greatly reduces the incidence of this type of cancer in women. Among the above mentioned SERMs, raloxifene has been widely used in prevention and treatment of postmenopausal osteoporosis and vertebral compression fractures, and clinical studies are now underway to test the comparative advantages of raloxifene with those of bazedoxifene, a more recently developed SERM. Research on a number of adverse side effects of SERM agents is being performed to determine the long-term safety of this class of compouds for treatment of osteoporosis.
